Header Image for Austedo vs Ingrezza Cost

Austedo vs Ingrezza Cost

Listen to the article instead of reading through it.
0:00

Overview

Austedo Information

Ingrezza Information

Effectiveness

Dosage Information

Side Effects

Safety Information

Cost

Market Information

Introduction

For patients with movement disorders such as Huntington's disease or tardive dyskinesia, certain drugs can help manage involuntary movements. Austedo and Ingrezza are two such prescription medications that are commonly used to help control these symptoms. They each impact different neurotransmitters in the brain to alleviate abnormal muscle movements associated with these disorders. Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor, affecting levels of dopamine, serotonin, norepinephrine, and histamine in nerve endings while preventing their uptake into synaptic vesicles. On the other hand, Ingrezza is a selective VMAT2 inhibitor primarily impacting dopamine levels by blocking its reuptake into neurons.

When considering costs between the two medications for managing movement disorders like tardive dyskinesia or Huntington’s disease - it depends on several factors including health insurance coverage and availability of manufacturer patient assistance programs. It’s always recommended to discuss this aspect thoroughly with your healthcare provider before making any decision.

Austedo vs Ingrezza Cost Side By Side

AttributeAustedoIngrezza
Brand NameAustedoIngrezza
ContraindicationsShould not be taken with MAO inhibitorsShould not be taken with MAO inhibitors
CostApproximately $11,000 for 60 tablets of 6 mgApproximately $13,500 for a month's supply of 40 mg
Generic NameDeutetrabenazineValbenazine
Most Serious Side EffectWorsening of mood or mental changes such as depression or suicidal thoughtsPossible severe allergic reactions
Severe Drug InteractionsMAO inhibitorsMAO inhibitors
Typical DoseVaries; can range significantly based on patient needStarts at 40 mg/day, can be increased to 80 mg/day

What is Austedo?

Deutetrabenazine (the generic name for Austedo) is a medication designed to treat movement disorders, such as Huntington's disease and tardive dyskinesia. It was first approved by the FDA in 2017. Austedo works by reducing the amount of certain chemicals in the body that are overly active in people with these conditions. On the other hand, Valbenazine (Ingrezza) is another medication used specifically for treating tardive dyskinesia. Ingrezza decreases the activity of a chemical in the brain that contributes to this disorder and was also FDA-approved in 2017.

Both medications aim at managing involuntary movements but they differ slightly on their influence on different neurotransmitters and side effects observed. While both drugs manipulate dopamine levels within the nervous system, Austedo has a broader impact due to its ability to affect more types of neurotransmitters compared to Ingrezza which mainly targets vesicular monoamine transporter 2 (VMAT2). Regarding cost considerations, it's crucial for patients considering these treatments to consult with healthcare providers or pharmacists about potential costs as prices can vary based on factors like insurance coverage, location, dose prescribed among others.

What conditions is Austedo approved to treat?

Austedo and Ingrezza are approved for the treatment of various movement disorders:

  • Austedo is used to treat chorea associated with Huntington’s disease, a disorder causing uncontrolled movements. It's also beneficial in treating tardive dyskinesia, involuntary movements usually caused by prolonged use of certain psychiatric drugs.

  • Ingrezza is specifically designed to treat adults suffering from tardive dyskinesia. Unlike Austedo, it doesn't have a direct application in managing symptoms of Huntington’s disease.

How does Austedo help with these illnesses?

Austedo and Ingrezza are both medications used to manage symptoms of tardive dyskinesia, a condition characterized by involuntary movements. Austedo works by regulating the amount of dopamine available in the synapses of the brain. It does this by inhibiting certain enzymes that metabolize dopamine, so levels can be maintained for longer periods of time. Dopamine is a neurotransmitter that plays an important role in movement regulation, mood, pleasure, and cognition among other things.

On the other hand, Ingrezza acts as a selective vesicular monoamine transporter 2 inhibitor which leads to decreased uptake into synaptic vesicles and depletion of neuronal stores of monoamines such as dopamine—resulting in reduced synaptic availability.

In terms of cost comparison between these two drugs for managing tardive dyskinesia—one must take into account not only their market prices but also factors like insurance coverage, duration & frequency of treatment required based on individual cases which varies from person to person. Therefore one cannot generally declare one drug more economical than the other without considering all these factors.

What is Ingrezza Cost?

Ingrezza, with its generic name being valbenazine, is a vesicular monoamine transporter 2 (VMAT2) inhibitor that has demonstrated effectiveness in reducing the symptoms of tardive dyskinesia - a neurological disorder characterized by involuntary movements. It was first approved by the FDA in 2017. As Ingrezza specifically targets VMAT2, it does not inhibit dopamine reuptake and thus differs from drugs like Austedo which are dopamine depletors.

This unique mechanism of action results in a different side-effect profile compared to other treatments for tardive dyskinesia: it's less likely to cause depression or suicidal ideation (common side effects associated with Austedo). Furthermore, Ingrezza tends to be more expensive than other treatment options due to its recent entry into the market and complex manufacturing process. However, many patients find this cost justifiable given its increased efficacy and better tolerability compared to traditional therapies such as Austedo.

What conditions is Ingrezza Cost approved to treat?

Ingrezza, a medication that can be considerably costly, is approved for the treatment of:

  • Tardive dyskinesia (TD), an often irreversible neurological disorder resulting from prolonged use of certain antipsychotic medications.

While the price tag may seem steep, it's essential to consider Ingrezza's effectiveness and potential ability to improve quality of life when comparing it with its counterparts like Austedo. It is always advised to consult with your healthcare provider before making any decision regarding these medications.

How does Ingrezza Cost help with these illnesses?

Ingrezza, another treatment option for tardive dyskinesia, works by blocking the vesicular monoamine transporter 2 (VMAT2) in nerve endings. This reduces dopamine release into synapses, thereby minimizing involuntary movements associated with this condition. The cost of Ingrezza can be a significant factor when considering treatment options, as it tends to be more expensive than other treatments such as Austedo. However, its once-daily dosing schedule and generally well-tolerated side effect profile may offset the higher cost for some patients. As usual, individual responses and experiences will vary; therefore it is crucial to consult with your healthcare provider before making a decision on whether Ingrezza or any other medication is right for you.

How effective are both Austedo and Ingrezza Cost?

Both deutetrabenazine (Austedo) and valbenazine (Ingrezza) have success in treating patients with tardive dyskinesia, a condition marked by involuntary movements often resulting from long-term use of certain psychiatric drugs. Austedo was approved by the FDA in 2017, following Ingrezza which was approved in the same year.

The effectiveness of Austedo and Ingreza was directly studied in several double-blind clinical trials where both medications demonstrated efficacy at controlling symptoms of tardive dyskinesia. The safety profiles for both drugs were promising as well. There is currently no significant difference between their efficacy rates or side effect profiles based on available data.

A recent cost analysis report on Deutetrabenazine revealed that it can be an expensive drug to maintain, especially considering its daily dosage requirement which may lead to higher out-of-pocket costs for some patients. It's important to note though that patient assistance programs are available which can help lower these costs significantly.

Valbenazine has shown similar effectiveness starting from the first week of treatment and beyond. Its side effect profile is also favorable with fewer reports about common side effects like sedation compared to other treatments for tardive dyskinesia. However, Valbenazine or Ingrezza is also considered relatively pricey but again patient assistance programs exist to aid those who need it.

When comparing both options financially, it will largely depend on individual insurance coverage and any applicable pharmaceutical company discounts or rebates that might be available.

abstract image of a researcher studying a bottle of drug.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is Austedo typically prescribed?

The cost of Austedo and Ingrezza can vary significantly based on dosages, location, insurance coverage, and other factors. On average, a month's supply of Austedo can range from $3,000 to $6,000 without insurance. The price for Ingrezza is similar; it costs around $5,300 per month for the 40mg/day dosage without insurance. For both medications, assistance programs may be available to help reduce these costs. As with any medication regimen, the cost should not be the only factor in deciding which treatment to use—effectiveness and side effect profiles are also crucial considerations.

At what dose is Ingrezza Cost typically prescribed?

Ingrezza treatment typically begins at a dosage of 40 mg/day. After one week, the dose can be increased to 80 mg/day taken as a single capsule once daily. Unlike Austedo which is dosed twice daily, Ingrezza's simpler regimen could potentially enhance compliance for some patients. However, it must be noted that the cost of Ingrezza may pose an obstacle for some people; monthly supply can run into thousands of dollars depending on insurance coverage and location. It's advisable to check with your insurance provider or look for patient assistance programs in order to manage the costs associated with this medication.

What are the most common side effects for Austedo?

Common side effects of Austedo include:

  • Insomnia and somnolence (sleepiness/drowsiness)
  • Headache
  • Diarrhea
  • Nausea
  • Dry mouth
  • Fatigue (general weakness and tiredness)
  • Upper respiratory tract infection
  • Decreased appetite

On the other hand, Ingrezza may cause side effects such as:

-Somnolence (sleepiness or drowsiness) -Dry mouth -Nasopharyngitis (common cold symptoms like runny nose, sore throat etc.) -Fatigue -Akathisia (feeling of restlessness leading to a need for constant movement)

It is important to note that everyone's body reacts differently to medications. Hence, you might not experience any of these side effects or could experience others not listed here. Always consult with your healthcare provider before starting new medication.

abstract image of a patient experiencing side effect

Are there any potential serious side effects for Austedo?

Austedo and Ingrezza are both used to treat different movement disorders, but they can have contrasting side effects. With Austedo, these may include:

  • The worsening of mood or mental changes such as depression or suicidal thoughts
  • Allergic reactions that might manifest in symptoms like hives, difficulty breathing, swelling in your face or throat
  • Vision disturbances including blurred vision or eye pain
  • Heart-related issues such as fast heartbeats and chest fluttering
  • Electrolyte imbalance leading to low sodium levels which could cause headache, confusion and loss of coordination

With Ingrezza on the other hand, you should watch out for:

  • Signs of allergic reactions: redness, itching skin rash with blistering and peeling
  • Cardiovascular problems indicated by shortness of breath and sudden dizziness
  • Severe muscular reaction - muscle stiffness accompanied by high fever and sweating -Disturbances in central nervous system function causing tremors.

Both medications require close monitoring for any signs of serotonin syndrome which can present as agitation, hallucinations among others. Always consult a healthcare provider if you experience severe adverse effects from either drug.

What are the most common side effects for Ingrezza Cost?

When considering Ingrezza, it's essential to weigh its cost and potential side effects. Some of the more common ones might include:

  • Sleepiness or drowsiness
  • Heart palpitations or increased heart rate
  • Dry mouth
  • Nausea, stomach discomfort, constipation
  • Headache and dizziness
  • Blurred vision
  • Swelling in extremities (hands, feet)

It is noteworthy that these symptoms are usually mild to moderate. However, if they persist or become severe, consult your healthcare provider promptly for guidance. Remember also that while some may find the cost of Ingrezza high compared to Austedo; it's crucial to consider its effectiveness and suitability for your specific condition in consultation with a medical professional before making a decision.

Are there any potential serious side effects for Ingrezza Cost?

When considering Ingrezza Cost, it is crucial to be aware of potential side effects. These may include:

  • Possible severe allergic reactions: signs could be hives, fever, and swollen glands. Difficulty in breathing or swelling in your face or throat should not be ignored.
  • Changes in mental health: including the emergence of suicidal thoughts or unusual shifts in mood and behavior.
  • Neurological issues such as seizures (convulsions) need immediate medical attention.
  • Vision problems might develop, characterized by blurred vision, tunnel vision, eye pain or swelling, even seeing halos around lights which are unusual visual phenomena.
  • Cardiovascular symptoms like fast or irregular heartbeats can also occur.

The cost of a medication often reflects its effectiveness and safety profile. However, if you experience any adverse events while taking Ingrezza Cost medication – regardless of how minor they may seem – seek professional medical advice promptly.

Contraindications for Austedo and Ingrezza Cost?

Both Austedo and Ingrezza, like many other medications for neurological disorders, may exacerbate symptoms in some individuals. If you notice the worsening of your condition or an increase in unusual thoughts or behaviors, please seek immediate medical attention.

Neither Austedo nor Ingrezza should be taken if you are currently taking certain psychiatric medications known as Monoamine oxidase (MAO) inhibitors. Always communicate with your healthcare provider about which drugs you are currently using; MAO inhibitors will necessitate a clearance period of approximately two weeks to prevent harmful interactions with either Austedo or Ingrezza.

When it comes to cost comparison between these two options, both Austedo and Ingrezza can carry significant costs without insurance coverage. It's important to discuss these factors with your healthcare provider as well as checking what is covered under your specific health plan before starting treatment.

How much do Austedo and Ingrezza Cost cost?

For the brand name versions of these drugs:

  • The price for 60 tablets of Austedo (6 mg) averages around $11,000 which works out to approximately $180-$360/day, depending on your dose.
  • The price for a month's supply of Ingrezza (40 mg), which is about 30 capsules, averages at about $13,500 or roughly $450/day.

Thus, if you are in the higher dosage range for Austedo (i.e., 24mg/day or higher), then brand-name Ingrezza may be less expensive on a per-day treatment basis. However, cost should not be a primary consideration in determining which drug is right for you.

Currently there are no generic versions available for either Austedo (deutetrabenazine) and Ingrezza (valbenazine). Both medications can have high costs associated with them due to their relatively recent market introductions and lack of generics. Always check with your healthcare provider and insurance company to understand the potential out-of-pocket costs associated with these medications.

Popularity of Austedo and Ingrezza Cost

Deutetrabenazine, with the brand name Austedo, was approved by the US FDA in 2017 for treating Huntington's disease-associated chorea (involuntary movements) and tardive dyskinesia. The exact number of prescriptions for Austedo isn't readily available; however, it has been seeing a steady increase in usage since its launch.

Valbenazine, sold under the brand name Ingrezza, is also a medication used to treat adults with tardive dyskinesia. Approved by the FDA in 2017 as well, Ingrezza was prescribed to an estimated several thousand people within its first few years on the market.

In terms of cost comparison between these two drugs that are both indicated for tardive dyskinesia treatment, there is little difference when comparing their list prices; both are priced at over $60K per year without insurance coverage. However, this doesn't factor into account negotiated discounts or patient assistance programs which could lower out-of-pocket costs.

Conclusion

Both Austedo (deutetrabenazine) and Ingrezza (valbenazine) are medications used to manage the symptoms of tardive dyskinesia, a motor disorder caused by long-term use of certain psychiatric drugs. These two treatments have been found effective in reducing the involuntary movements associated with this condition according to various clinical trials.

In terms of cost, both these medicines may be quite expensive as they are relatively new innovations in treatment and currently do not have less costly generic versions available. This can pose a significant financial burden, particularly for patients who must bear the costs themselves.

Austedo and Ingrezza work differently at the neurological level: Austedo inhibits VMAT2 (a protein involved in neurotransmitter release), while Ingrezza acts selectively on VMAT2 without affecting other monoamine transporters. The decision between these two drugs is typically based on an individual's specific medical history and needs.

Side effects for both drugs include sleepiness or sedation, dry mouth, constipation, blurred vision among others; however side effect profiles vary somewhat between them. For instance, cardiovascular side effects appear more frequently with Austedo than with Ingrezza. As always when starting any new medication regimen it is important that patients closely monitor their health status and promptly report any adverse changes to their healthcare provider.

Refrences

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top